B2M and B-cell chronic lymphocytic leukemia: The International Predictive Index for CLL (CLL‐IPI) classifies patients into four risk groups (low, moderate, high, and very high) based on TP53 and IGHV mutation status, serum beta‐2 microglobulin (B2M) concentration, clinical stage, and age.